Skip to content
Terminus Peptides
Sign inContact
  • Research use only — not for human or veterinary use
  • 67 compound profiles, every source cited
  • 63 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status

Research profile · Protein

Botulinum toxin

Also known as BoNT

Clinical — evidence level 4 of 4: Established clinical evidencePrescription only — UK regulatory status: Prescription-only medicine (UK)

Overview

A neurotoxic protein that blocks acetylcholine release. A prescription-only medicine in the UK, and a Schedule 5 toxin under anti-terrorism law.

Category
Protein
Highest evidence level identified
Established clinical evidence
Last scientifically reviewed
22 August 2026
Last regulatory review
22 August 2026

Mechanism under investigation

Botulinum neurotoxins are zinc metalloproteases produced by Clostridium botulinum: a heavy chain binds receptors on peripheral cholinergic nerve terminals and delivers a light chain into the cytosol, where it cleaves SNARE proteins — SNAP-25 for the widely used type A — abolishing the membrane fusion step of acetylcholine release. The result is flaccid paralysis of the affected terminal lasting weeks to months until the terminal remodels. The same mechanism is the disease botulism and, at nanogram doses placed precisely, the medicine.

Research areas

  • Neuromuscular physiology
  • Toxinology

These are fields in which the compound has been investigated. Listing a field is not a statement that anything was demonstrated within it.

Current evidence

In-vitro evidence

Cells, tissues or biochemical systems outside a living organism.

Characterised in exceptional detail: receptor binding partners, translocation, SNARE substrate specificity of each serotype, and the structural biology of the light-chain protease.

Animal evidence

Studies in living non-human animals.

Extensive, from classical toxinology — including the potency work that makes it, per unit mass, the most lethal substance known — to the preclinical pharmacology behind each licensed indication.

Human observational evidence

Studies observing people without assigning an intervention.

Decades of clinical use across neurology, urology, ophthalmology and aesthetics, with large registry and pharmacovigilance datasets, including documented iatrogenic botulism from counterfeit and mis-dosed product.

Clinical-trial evidence

Studies assigning an intervention to human participants.

Extensive within licensed indications, including Cochrane review support in chronic migraine, where onabotulinumtoxinA reduced monthly migraine days modestly against placebo. Trial evidence and licences are strictly product- and indication-specific, because units are not interchangeable between brands.

Study limitations

  • Every trial result is specific to a named product, dose in that product’s units, injection site and indication; none of it generalises to unlicensed material.
  • Doses are measured in units defined by bioassay, and unit potency differs between brands — the property that has caused real-world overdoses.
  • Aesthetic-use evidence measures appearance scales over weeks, not long-term outcomes.
  • Spread of toxin beyond the injection site is a recognised, occasionally serious adverse event even with licensed product placed by trained clinicians.

UK regulatory context

Prescription-only medicine (UK)

A medicine that may lawfully be supplied in the UK only against a prescription from an appropriate practitioner.

Source: BOTOX 100 Allergan Units Powder for solution for injection — Summary of Product Characteristics (opens medicines.org.uk in a new tab) (electronic Medicines Compendium)

Regulatory classification is jurisdiction-specific. A compound authorised elsewhere is not thereby authorised in the UK, and a supplier’s description of a substance does not determine how it is classified in law. See safety and regulation for the framework and the authoritative sources.

Safety and interpretation

Botulinum toxin sits under two regimes at once, and both point the same way. As a medicine it is prescription-only, administered at nanogram-scale doses by trained clinicians using licensed products whose units are brand-specific. As a substance it is listed under Schedule 5 of the Anti-terrorism, Crime and Security Act 2001, which places security obligations on holding it at all — a classification reflecting that it is, per unit mass, the most potent toxin known. Iatrogenic botulism from counterfeit or wrongly dosed product is documented and can require ventilation. This is the one material in this library for which the site’s standard research-use framing is not the operative constraint: security law is. Terminus Peptides does not supply it.

References